FE 204205

Drug Profile

FE 204205

Alternative Names: FE-204205

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class
  • Mechanism of Action Vasopressin 1a receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ascites; Portal hypertension

Most Recent Events

  • 27 Sep 2017 Ferring Pharmaceuticals terminates a phase I trial in Portal hypertension in Spain due to difficult recruitment (IV)(NCT02929407)
  • 01 Nov 2016 Phase-I clinical trials in Portal hypertension in Spain (IV) (NCT02929407)
  • 07 Oct 2016 Ferring Pharmaceuticals plans a phase I trial for Portal hypertension in Spain (IV) (NCT02929407)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top